A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia"
DOI: 10.1038/s41375-021-01256-8
Abstract: The most common chemotherapy backbone for children with mature B-non Hodgkin lymphoma (B-NHL), Burkitt’s lymphoma (BL), and diffuse large B-cell lymphoma includes short intensive therapy including steroids, high dose methotrexate, fractionated cyclophosphamide, anthracycline, and intrathecal… read more here.
Keywords: lymphoma; risk; dense rituximab; dose dense ... See more keywords